Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C102784
http://purl.obolibrary.org/obo/NCIT_C102784
|
|---|---|
| Preferred Name | Talacotuzumab |
| Definitions |
A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, talacotuzumab binds to and neutralizes CD123. This may inhibit IL-3-dependent signaling and may inhibit proliferation and differentiation in CD123-positive tumor cells. CSL362 contains an engineered Fc region which increases its binding affinity to Fc-gamma receptors on the surface of natural killer (NK) cells thereby initiating antibody-dependent cellular cytotoxicity (ADCC). CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. Upon intravenous administration, talacotuzumab binds to and neutralizes CD123. This may inhibit IL-3-dependent signaling and may inhibit proliferation and differentiation in CD123-positive tumor cells. CSL362 contains an engineered Fc region which increases its binding affinity to Fc-gamma receptors on the surface of natural killer (NK) cells thereby initiating antibody-dependent cellular cytotoxicity (ADCC). CD123 is normally expressed on committed blood progenitor cells in the bone marrow; its overexpression is associated with increased leukemic cell proliferation and aggressiveness. |
|---|---|
| prefLabel | Talacotuzumab
|
| label | Talacotuzumab
|
| NCI_META_CUI | CL437022
|
| PDQ_Closed_Trial_Search_ID | 736467
|
| code | C102784
|
| Has_Target | |
| prefixIRI | NCIT:C102784
|
| in_subset |
See more
See less
|
| Display_Name | Talacotuzumab
|
| Preferred_Name | Talacotuzumab
|
| FDA_UNII_Code | X8JR0I7JE1
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Talacotuzumab
|
| CAS_Registry | 1826831-79-1
|
| NCI_Drug_Dictionary_ID | 736467
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 736467
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |